Abstract. Oncostatin M (OSM), a pleiotropic cytokine, can either promote or inhibit the growth of tumors derived from specific tissues. However, little is known about the activity and expression pattern of OSM in endometrial cancers (ECs). Herein we show that expression of OSM in human ECs was significantly higher than that in hyperplastic or normal tissues. In EC tissues, high OSM levels were positively correlated with tumor stage, histological grade, myometrial invasion, and lymph node metastasis. Additionally, we demonstrated that recombinant human OSM (rhOSM) promoted tumor angiogenesis in EC cell lines by activating STAT3 (signal transducer and activator of transcription 3) and enhanced both cell migration and cell invasion. rhOSM did not, however, influence the proliferation of EC cells in vitro. In contrast, in our in vivo xenograft model, overexpression of rhOSM promoted cell proliferation, tumor growth, and angiogenesis in nude mice. Collectively, these experiments suggest that OSM may be a tumor promoter that encourages EC progression. OSM may thus serve as a potential target of antiangiogenic therapy for endometrial cancer.
Introduction
Endometrial cancer (EC) is one of the most common gynecologic malignancies, with an estimated 49,500 new cases and 8200 deaths in 2013 in the United States (1) . ECs are classified into two groups: those that are estrogen related (type I, endometrioid) and those that are not estrogen related (type II, non-endometrioid). Type I ECs are usually linked to obesity, hormone-receptor positivity, and a favorable outcome. In contrast, type II ECs are more common in older, non-obese women and have a worse prognosis (2) . Current treatment, including hysterectomy, hormonal therapy, and chemotherapy, are only effective for early-stage ECs. Effective target therapies are not available for patients with high-grade diagnoses, especially for individuals with undifferentiated tumors with deep muscle infiltration (3) . Despite the prevalence of this cancer, molecular mechanisms accounting for the development and metastasis of EC remain unclear. To allow for the possibility of targeted therapies for later-stage EC, further exploration into the molecular mechanisms underlying EC progression would be beneficial.
Oncostatin M (OSM) is a member of the IL-6 family of cytokines produced by macrophages, monocytes, T cells, neutrophils, and several other cell types (4, 5) . OSM inhibits the growth of cells from several types of solid tumor, including breast tumor, melanoma, and osteosarcoma (6) (7) (8) . In contrast, OSM promotes the proliferation of cells from other tumor types, including those derived from prostate, cervical, and ovarian cells (9) (10) (11) . These results suggest that OSM may have different roles depending on the tumor cell type. The role that OSM plays in EC has not been clearly defined.
OSM signals through a heterodimeric receptor composed of gp130 and either OSM receptor-b (OSMR) or the leukemia inhibitory factor receptor (LIFR). These signal via Janus kinases (JAKs) to activate the STAT3 (signal transducer and activator of transcription 3), PI3K (phosphatidylinositol-3-kinase), and MAPK (mitogen-activated protein kinase) cascades (12) (13) (14) . Increased STAT3 activity in tumor cells upregulates VEGF expression and enhances angiogenesis (15) , which has a major role in tumor growth, progression, and metastasis (16, 17) . However, it remains unclear whether OSM contributes to the development and progression of EC and, if it does, what the mechanism of its action is, especially with respect to angiogenesis, which involves the STAT3/VEGF pathway.
In this study, we sought to explore the functional, mechanistic roles of OSM in EC. We analyzed OSM expression in paraffin-embedded tissue sections and function in multiple cellular contexts and assayed its effects in tumor-bearing nude mice. We showed that OSM promoted EC progression. In particular, OSM promoted angiogenesis in a STAT3-dependent manner and, therefore, may serve as a potential marker for antiangiogenic therapy selection.
Materials and methods
Acquisition of tissue specimens. Paraffin-embedded tissue samples were obtained from patients who were treated at the Shanghai First People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China. The project was approved by the Human Investigation Ethics Committee of the Shanghai First People's Hospital, and informed consent were obtained from all patients prior to the onset of the study. We obtained 73 EC tissue specimens from patients who underwent initial hysterectomy, 26 normal endometrial samples from patients who underwent hysterectomy to treat other diseases such as myoma or adenomyosis, and 20 atypical hyperplastic tissue specimens from patients who underwent hysteroscopic examination due to irregular bleeding. The stages (I-IV) and histological grades (G1-G3) of these tumors were established according to the criteria of the International Federation of Gynecology and Obstetrics (FIGO) surgical staging system (18) . none of the patients had undergone hormone therapy, radiotherapy, or chemotherapy before surgery. The clinicopathological characteristics of the EC patients participating in our study are presented in Table I .
Immunohistochemistry analysis. All samples were prepared and analyzed with the Histostain-Plus kit (rabbit) (MRBiotech, Emeryville, CA, USA) according to the manufacturer's protocol. Staining was performed on paraffin-embedded specimens using primary antibodies as follows: anti-OSM (1:100; Boster, Wuhan, China). After 16 h of incubation, the sections were incubated with a biotinylated secondary antibody (MRBiotech). We then added a horseradish peroxidase-conjugated avidinbiotin complex to the sections. OSM expression was detected by diaminobenzidine as per the manufacturer's instructions. The staining percentage was scored in the following manner: 0, 0-5%; 1, 5-25%; 2, 25-50%; 3, 50-75%; and 4, 75-100%. The staining intensity was scored as follows: 0, negative; 1, weak; 2, moderate; 3, strong. Then, immunoreactivity scores for each case were obtained by multiplying the values of the two para meters described above. As a negative control, phosphatebuffered saline (PBS) was used to replace the primary antibody.
Microvessel density (MVD) was assessed by immunostaining for CD34 (Abcam, Cambridge, UK), which highlights the tumor/tissue vascularity. The microvessels were counted in three fields per section. The positive-stained blood vessels in the selected areas were analyzed at x400 magnification.
Cell culture. The human EC cell lines Ishikawa and HEC-1B were used (American Type Culture Collection, Manassas, VA, USA). The human umbilical vascular endothelial cells (HUVECs) that we used were obtained from Key-Gen Biotech (nanjing, China). Ishikawa and HEC-1B cells were maintained according to the supplier's instructions in DMEM/F12 (Gibco, Auckland, new Zealand) supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA). HUVECs were grown in RPMI-1640 (Gibco) supplemented with 10% FBS. Cells were cultured in a humidified atmosphere with 95% air/5% CO 2 at 37˚C.
RNA extraction and quantitative real-time PCR. Total RnA was prepared from the EC cell lines using TRIzol RnA isolation reagents (Invitrogen, Carlsbad, CA, USA), and cDnA was then generated with the Prime Script RT reagent kit (Takara Inc., Otsu, Japan), using the manufacturer's instructions. A 10-µl PCR reaction with single-stranded cDnA as the template was carried out with 40 cycles of denaturation (95˚C) for 5 sec, annealing (60˚C) for 34 sec, and elongation (60˚C) for 30 sec using SYBR Premix Ex Taq (Takara Inc.). The primer sequences are listed in Table II . For all qPCR experiments, values on the y axis represent 2 (-∆Ct) , where ∆Ct is the difference between the Ct for the gene of interest and the Ct for the gene used for normalization. All data were obtained in triplicate from three independent experiments.
Enzyme-linked immunosorbent assay (ELISA). VEGF and OSM protein levels were detected in the culture medium using solid-phase sandwich ELISA assays as per the manufacturer's instructions (DVE00, R&D Systems, Minneapolis, Mn, USA and EK0478, Boster). According to the manufacturer, the VEGF assay sensitivity was 0.7 pg/ml, and the assay range was 15.6-1000 pg/ml. The OSM assay sensitivity was 0.7 pg/ml, and the assay range was 15.6-1000 pg/ml. Culture medium was collected three times independently for statistical analysis.
Western blot analysis. Total protein was extracted using a RIPA kit (Beyotime, Shanghai, China) containing a 1% dilution of the protease inhibitor phenylmethylsulfonyl fluoride (Beyotime) as per the manufacturer's instructions. Total protein concentration was estimated using the BCA method (Pierce, Rockford, IL, USA) as per the manufacturer's instructions. Similar amounts of protein were analyzed in each lane of a 10% SDS-polyacrylamide gel. Proteins were then transferred onto nitrocellulose membranes. After transfer, membranes were blocked with 5% bovine serum albumin (BSA)/ phosphate-buffered saline (PBS) for 2 h. The membranes were incubated with primary antibodies at 4˚C overnight. The membranes were then incubated with peroxidase-linked secondary antibody (1:10,000; Epitomics, Burlingame, CA, USA) for 2 h at room temperature. Proteins were then detected by enhanced chemiluminescent reagents. GAPDH was used as an internal control.
Primary antibodies included: rabbit anti-STAT3 (1:1000; Cell Signaling Technology, Beverly, MA, USA), rabbit antipSTAT3(1:1000; Cell Signaling Technology) and rabbit anti-GAPDH (1:2000; Epitomics).
Stable transfection of HEC-1B cells.
To stably express OSM, HEC-1B cells were washed with PBS and switched to antibiotic-free growth medium for 24 h before transfection. All transfections used Lipofectamine 2000 reagent (Invitrogen) as per the manufacturer's instructions. The plasmid that overexpressed OSM and the negative control (NC) plasmid were generated by GeneChem (Shanghai, China), the transfection reagent was obtained from Qiagen (Shanghai, China). The plasmid was transfected into HEC-1B cells (1.6 µg/ml), and then the cells were selected with G418 (1 mg/ml; Gibco, Carlsbad, CA, USA) in the growth medium and resistant clones were chosen.
Cell migration and invasion assays. After being trypsinized, centrifuged, and resuspended, cells were seeded in serum-free medium in the upper compartment of individual transwell chambers (8-µm pore size; BD Biosciences, San Jose, CA, USA) with or without Matrigel coating (BD Biosciences) at a density of 1x10 5 cells/well (for the migration assay) or 2x10 5 cells/well (for the invasion assay). The lower chamber was filled with 600 µl of culture medium containing 5% FBS (C5), C5 with 40 ng/ml rhOSM (C5/rhOSM), or C5 with 40 ng/ml rhOSM and 1 µM WP1066, a STAT3 inhibitor (C5/rhOSM/WP1066). After 24 h of incubation, cells that had failed to invade were removed from the upper chamber. Those that were attached to the outside of the membrane were fixed and stained with 5% crystal violet and counted at x200 magnification. Six random fields were selected for each membrane, and results are expressed in terms of the number of cells per field. The migration and invasion assays were repeated at least three times.
Evaluation of cell proliferation. Cell proliferation was evaluated with a CCK8 (Obio Technology, Shanghai, China) assay as per the manufacturer's instructions. Cells (2x10 3 cells/well) were plated in 96-well plates and were then cultured for 24, 48, or 72 h. At each time point, 10 µl of CCK8 stock solution was added to each well, and the plates were further incubated for 2 h at 37˚C. The absorbance was detected at 450 nm in a microplate reader. 
HEC-1B conditioned medium (CM) and mouse Matrigel plug assays.
HEC-1B cells were grown in C10. After 24 h, C10 was removed and replaced with culture medium without FBS (C0), C0 with 40 ng/ml rhOSM (C0/rhOSM), or C0 with 40 ng/ml rhOSM and 1 µM WP1066 (C0/rhOSM/WP1066). Samples of conditioned medium (CM) were obtained from each culture after an additional incubation of 24 h.
For the plug assay, nine athymic nude BALB/c mice were randomly divided into three groups. Growth factor-reduced Matrigel (300 µl; BD Biosciences) was mixed with CM (100 µl) and injected subcutaneously into the flank of a mouse. Mice were euthanized 18 days after inoculation, and plugs were removed and photographed. Matrigel plugs were stained with hematoxylin and eosin (H&E) for histological examination and were analyzed by immunohistochemistry as described above using antibodies against mouse CD34 (1:100, Abcam).
Tube formation assay. We coated a 96-well plate with 100 µl Matrigel per well and incubated the plate at 37˚C for 2 h. Then, 2x10 4 HUVECs were suspended in 1 ml diluted HEC-1B CM (dilution in 1:10) and applied to the pre-coated 96-well plate at a density of 2000 cells/well (19) . After incubation at 37˚C for 16 h, morphologic changes were observed under a microscope, and cells were photographed at x100 magnification. The total length of the capillary-like tubes that had formed was determined and averaged across three randomly selected microscope fields for each well.
HUVEC migration assays. To assess HUVEC migration ability, 5x10 4 cells suspended in 200 µl of RPMI-1640 were seeded in the upper chamber of a Transwell. The lower chamber was filled with HEC-1B CM from different sources as described in the plug assay. After 24 h of incubation, cells were analyzed as described above for the cell migration and invasion assays.
Statistical analyses. All tests were carried out with SPSS 17.0 (Microsoft, Redmond, WA, USA) or Prism (GraphPad, San Left, representative micrographs were taken at x200 magnification. Right, the number of migrating cells averaged from six random images from each treatment group at x200 magnification. (B) Transwell invasion assays of HEC-1B and Ishikawa cells with the same media as in (A). For both panels, left, representative micrographs were taken at x200 magnification, and, right, the number of invading cells were averaged across six random images from each treatment group at x200 magnification. The number of migrating or invading cells from three independent experiments is shown as the mean ± SD in the right panel ( * p<0.05, ** p<0.01).
Diego, CA, USA). Each experiment was performed at least three times. Where applicable, data are shown as the mean ± SD. Data were analyzed by unpaired Student's t-test or by one-way analysis of variance (AnOVA) for multiple comparisons. The Kruskal-Wallis rank test or Mann-Whitney U test were used for comparisons of the categorical data. A P-value of <0.05 was considered statistically significant.
Results

Expression of OSM in tissues and its association with clinicopathological parameters.
We assessed whether OSM is commonly upregulated in clinical EC samples. We chose 26 samples of normal endometrium tissue, 20 samples of atypical hyperplastic endometrium tissues, 57 cases of endometrioid endometrial cancer (EEC) tissue, and 16 cases of papillary serous EC or clear cell EC tissue. Immunohistochemistry showed that OSM expression was higher in atypical hyperplasias and even higher in ECs when compared with normal endometrial tissues (Fig. 1) . We calculated a composite histoscore to account for both stain intensity and uniformity to investigate whether the change in OSM expression in ECs was associated with specific clinical characteristics. We compared the association of OSM expression with the clinicopathological parameters of the EC cases (Table I) . Our analyses indicated a significant association between increased OSM expression and the depth of myometrial invasion, lymph node metastasis, advanced disease stage (stages III or IV), and poor histological differentiation (grade 3) (all measurements resulted in P<0.05; Table I ). However, there was no significant difference in OSM expression when comparing endometrioid and non-endometrioid (i.e., serous and clear cell histological subtypes) ECs (P=0.255; Table I ). These results suggested that OSM expression is related to the development of EC and to the risk-associated clinical features of the disease.
STAT3 is required for OSM-enhanced migration and invasion of EC cells.
We next examined the effect of rhOSM on EC cell migration and invasion in vitro. Transwell migration and invasion assays were performed to study the migratory and invasive ability of EC cells (Fig. 2) . rhOSM promoted cell migration and invasion in Ishikawa and HEC-1B cells (P<0.01). However, when the STAT3 inhibitor WP1066 was added, the effect was reversed. These results suggested that the effects of rhOSM in mediating EC cell migration and invasion are mediated by STAT3.
rhOSM does not directly promote cell viability in vitro.
To investigate the potential role of rhOSM in EC cell proliferation, HEC-1B and Ishikawa cells were stimulated with rhOSM (Fig. 3) . CCK8 proliferation assays revealed that rhOSM does not have a direct effect on HEC-1B or Ishikawa cell growth.
rhOSM upregulates STAT3 activity in EC cell lines. Although activation of STAT3 by rhOSM occurs in several cell types, it is unclear whether rhOSM can lead to STAT3 activation in EC cells. Thus, EC cells were serum starved and then stimulated with rhOSM (40 ng/ml) for 0 min, 5 min, 15 min, 30 min, 1 h, or 2 h before cells were collected for western blotting (Fig. 4) . Basal levels of phosphorylated STAT3 were very low in both cell lines; however, stimulation with rhOSM led to an increase in STAT3 phosphorylation. The peak values appeared after a 15-min (Fig. 4A ) and 1-h (Fig. 4B ) exposure to rhOSM in HEC-1B and Ishikawa cells, respectively. The total STAT3 protein levels remained fairly stable throughout the time points measured. OSM increased VEGF secretion in EC cells. VEGF is the main STAT3-regulated gene product (20) . Thus, we assessed the impact of OSM on VEGF expression in HEC-1B cells. Based on qRT-PCR, VEGFA mRnA expression increased in HEC-1B cells after rhOSM stimulation (Fig. 5A) . We also detected VEGF secretion in the CM of HEC-1B cells via ELISA. rhOSM stimulation increased VEGF secretion in HEC-1B cells (Fig. 5B) . However, VEGF secretion was not increased in cells treated with rhOSM and WP1066.
OSM histoscore ------------------------------------------
STAT3 activation mediates OSM-induced angiogenesis.
VEGF is a major regulator of tumor angiogenesis (21) . To further investigate whether rhOSM affects VEGF-based angiogenesis in ECs, we used three different approaches to investigate whether and how OSM could regulate the behavior of endothelial cells. CM was collected from HEC-1B cells cultured with C0, C0/rhOSM, or C0/rhOSM/WP1066 for 24 h. First, to investigate whether rhOSM altered the functional behavior of endothelial cells, we used a tube formation assay. HUVECs were placed on a basement membrane matrix in the presence of CM. Tube formation was quantified by averaging the total length of tubes in three randomly chosen microscope fields. CM from HEC-1B cells stimulated by rhOSM significantly promoted tube formation (Fig. 5D ). Second, we tested whether HUVEC migration ability was affected by differing conditions with the use of a transwell chamber assay. The migration ability of HUVECs increased in the C0/rhOSM group, whereas addition of WP1066 partially inhibited these effects (Fig. 5C ). Thus, OSM may act as a pro-angiogenesis molecule in EC cells by promoting the migration of vascular endothelial cells.
To further confirm this effect in vivo, we performed a mouse angiogenic Matrigel plug assay. We mixed HEC-1B CM with growth factor-reduced Matrigel and injected the resulting plugs into mouse flanks. The plugs were removed 18 days after injection (Fig. 5E ) and were stained with H&E (data not shown) or immunostained for CD34. The inclusion of C0/rhOSM CM led to significantly induced blood vessel formation in Matrigel, whereas the C0/rhOSM/WP1066 CM inhibited these effects. These results suggested that rhOSM stimulation leads to a large increase in angiogenic events and that these events are STAT3 dependent.
Oncogenic role of OSM in an in vivo tumor xenograft model.
To further assess the role of OSM in the progression of EC, we performed tumorigenicity assays in nude mice. We constructed HEC-1B cell lines that were stably transfected with plasmid overexpressing either OSM or nC. The transfected cells were then injected into the mice subcutaneously. Five weeks after injection, the sizes and weights of tumors were significantly larger in the OSM-overexpressing group as compared with the nC group (Fig. 6B and C) . Tumor tissues were then embedded in paraffin, sectioned, and stained with H&E and immunolabeled with antibodies against OSM, CD34, Ki67, or PCnA (Fig. 6D ). Ki67 and PCnA expression was used to assess proliferation indices. Increased expression of Ki67 and PCnA in the OSM-overexpressing group was consistent with larger tumor volumes in these animals (Fig. 6B-D) . Taken together, these results suggested an important role for OSM in regulating tumor growth in EC.
Discussion
The expression of OSM has been studied in several human malignancies and cell types, and the results suggest it has a dual function (22) . However, the role of OSM expression or activity in EC remains unclear. Herein, we show that OSM expression was significantly increased in human atypical endometrial hyperplasia and invasive cancers as compared with normal endometrium. Moreover, increased OSM expression levels were positively correlated with the depth of myometrial invasion, disease stage, histological grade and lymph node metastasis of ECs, which are important prognostic factors (23) . These data suggest that overexpression of OSM contributes to the progression of human EC.
Solid tumor growth is largely dependent on successful neovascularization, and several factors, the most notable of which are VEGFs, promote tumor angiogenesis. Our findings that VEGF secretion and VEGFA mRnA levels were correlated with different proangiogenic abilities in the CM from the HEC-1B EC cell line provide further support for the involvement of this mechanism. Increased VEGF expression is found in 56-66% of EC tumors (24) . VEGFA expression is an independent predictor of a poor prognosis in patients with EEC (24) (25) (26) . Based on the above results, we suggest that OSM may play an important role in angiogenesis regulation in EC.
STAT3 is a 92-kDa transcription factor, whose gene is located on chromosome 17q21 in humans. Activated STAT3 forms homo-and heterodimers that translocate to the nucleus, bind to the promoter region of specific target genes, and regulate gene transcription. Overexpression of STAT3 was found in several cancers, such as lung (27, 28) , head and neck (29), stomach (30, 31) , and colorectal (32, 33) carcinomas. Previous studies have shown that in certain cell lines, OSM induces the activation of STAT3 (34) .
In our study, we demonstrated that in HEC-1B and Ishikawa cells, STAT3 was activated after exposure to rhOSM. We further investigated the effects of rhOSM on the migration and invasion of EC cells and found that rhOSM markedly promoted cell migration and invasion in HEC-1B and Ishikawa cells. These findings are consistent with our immunohistochemical analysis, which showed that higher expression of OSM is found in tumors that displayed a greater depth of myometrial invasion. However, the effect was reversed when WP1066 was added. This suggests that OSM-induced migration and invasion are both regulated by the signaling of OSM-induced STAT3 activation. We also showed that rhOSM promoted VEGF secretion in HEC-1B cells and that the CM taken from these treated cells led to an increase in tube length in HUVECs in the tube formation assay and increased MVD in plugs in the mouse Matrigel plug assay. This phenomenon was reversed when the cells were exposed to WP1066. Since activated STAT3 binds to the VEGF promoter (15) , rhOSM may activate STAT3, which thereby induces VEGF expression. However, our data do not completely rule out the possibility that other signaling pathways, in addition to STAT3, are involved. The identification of additional rhOSM-induced pathways and the determination of the specific molecular mechanism responsible for the OSM-STAT3 interaction are aspects that warrant further study.
Whereas some studies have confirmed that OSM inhibits proliferation in melanoma, osteosarcoma, and neuroblastoma cancer cells (35, 36) , other studies have shown a direct proproliferative effect on Kaposi's sarcoma and Ewing sarcoma cells (37, 38) . In our study, OSM did not directly stimulate proliferation of either HEC-1B or Ishikawa cells in vitro; however, in the mouse xenograft model, it was able to promote proliferation and resulted in larger tumor volumes. Recent research shows that overexpression of OSM promotes tumor growth, and does so through alteration of the tumor environment with the accumulation of M2 macrophages (39) . Whether this kind of mechanism exists in ECs is still unclear and requires further investigation.
In summary, our study demonstrates that OSM plays important roles during EC progression, especially in the regulation of angiogenesis. These findings suggest that OSM may be a valuable prognostic biomarker for EC progression and that it could offer a novel potential therapeutic strategy for ECs. Although our results are promising, additional investigations are required to further define the long-term consequences of anti-OSM treatment.
